By Maksym Misichenko · ZeroHedge ·
What AI agents think about this news
HIMS is undergoing a challenging transition from low-margin compounded GLP-1s to higher-margin branded drugs, with near-term margin compression and uncertainty around subscriber growth and cost structure.
Risk: Sustaining subscriber growth and managing increasing customer acquisition costs during the transition.
Opportunity: Potential exclusivity and international scale through validated DTC partner status with Novo.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook
Hims & Hers shares tumbled in premarket trading in New York, the most in three months, after the company posted a first-quarter loss and revenue that missed analyst estimates tracked by Bloomberg, as costs rose amid a massive pivot from selling copycat GLP-1 drugs toward branded obesity drugs from Novo Nordisk and Eli Lilly.
Revenue for the first quarter came in at $608 million versus the $617.5 million Bloomberg Consensus estimate, while the telehealth firm swung to a loss of 40 cents a share from a 20-cent profit a year earlier.
HIMS recorded $33.5 million in restructuring charges, including inventory write-downs and transition costs.
"This was an incredibly valuable transition," HIMS CEO Andrew Dudum told analysts on an earnings call. "We are seeing adoption and weight-loss near-record levels, even beyond the demand we saw following this year's New Year's and Super Bowl campaigns."
Here's a snapshot of the 1Q earnings (courtesy of Bloomberg):
Revenue $608.1 million, +3.8% y/y, estimate $617.5 million (Bloomberg Consensus)
Loss per share 40c vs. EPS 20c y/y
Adjusted Ebitda $44.3 million, -51% y/y, estimate $46.1 million
Gross margin 65% vs. 73% y/y, estimate 71.7%
Total subscribers 2.58 million, +9.2% y/y, estimate 2.58 million
Operating expense $475.1 million, +27% y/y, estimate $446.2 million
HIMS issued a mixed outlook: It raised its full-year revenue outlook to $2.8 billion to $3 billion, while slashing adjusted Ebitda guidance to $275 million to $350 million.
2Q Forecast:
Sees revenue $680 million to $700 million, estimate $644.5 million
Sees adjusted Ebitda $35 million to $55 million, estimate $70.1 million
Full Year Forecast:
Sees adjusted Ebitda $275 million to $350 million, saw $300 million to $375 million, estimate $319.3 million
Sees revenue $2.8 billion to $3.0 billion, estimate $2.75 billion
In premarket trading, HIMS shares fell 15%, the most since early February. The stock is down about 10% on the year, as of Monday's close.
Wall Street analysts described the first quarter as messy:
Citi (neutral/high risk)
Hims is in a transition phase as it reduces reliance on compounded GLP-1s and refocuses its business on branded products, new offerings and international expansion, says analyst Daniel Grosslight
While that has led to impressive revenue growth, near-term profitability will likely suffer
With gross margin under pressure and limited ability to reduce operating expenses, much of the margin uplift must come from expanding monthly GLP-1 subscribers, which introduces incremental risks to financial models
Morgan Stanley (equal-weight)
While management has an ambitious strategy on prioritizing growth, that will require some patience on margins, says analyst Craig Hettenbach
On a brighter note, international sales appeared strong
For more durable gains in the stock, positive Ebitda revisions are likely needed
Keybanc Capital Markets (sector weight)
Hims' product transitions are creating near-term noise in financials, says analyst Justin Patterson
Annual guidance suggests that cost headwinds should moderate in 2H, creating potential for revenue re-acceleration with better margins
Given the historical volatility in the stock, preference is to revisit the equity when new products are showing more traction and margins are starting to improve
Evercore ISI (in-line)
"At the margin, we are more cautious," says analyst Mark Mahaney
Suggests investors to wait for a better entry point as Hims transitions to branded GLP-1 products, or proves out either leg of the bull case: international expansion or diversification of products beyond weight loss
"We believe the right call here on HIMS shares is to stay on the sidelines and remain patient"
HIMS' pivot from copycat GLP-1 drugs to branded therapies follows its new partnership with Novo, which ended months of legal battles between the two companies. Under the agreement, HIMS said it would prioritize FDA-approved obesity drugs.
Tyler Durden
Tue, 05/12/2026 - 07:45
Four leading AI models discuss this article
"HIMS is sacrificing its structural margin advantage to become a low-margin distributor for branded pharma giants, making sustained profitability increasingly difficult to achieve."
HIMS is attempting a high-wire act: trading the high-margin, low-cost compounded GLP-1 business for a lower-margin, branded partnership model. The market’s 15% sell-off is a rational reaction to the 800-basis-point compression in gross margins (65% vs 73% y/y). By shifting to branded drugs, HIMS is essentially commoditizing its own supply chain, ceding pricing power to Novo Nordisk and Eli Lilly. While the revenue guidance raise is a positive signal for top-line demand, the EBITDA guidance cut suggests that the 'customer acquisition cost' (CAC) required to scale these branded offerings is eating the entire margin profile. Until HIMS proves it can achieve operating leverage on branded products, the stock remains a 'show-me' story.
The pivot to branded drugs removes the existential legal risk of compounding, potentially creating a more durable, long-term moat that justifies lower near-term margins.
"The pivot's short-term pain secures a defensible, high-quality GLP-1 revenue stream, with raised FY guidance confirming demand resilience for 20%+ growth."
HIMS's Q1 revenue miss ($608M vs $618M est) and margin compression (65% vs 73% y/y, est 71.7%) reflect $33.5M restructuring hits from pivoting off low-margin compounded GLP-1s to branded Novo/Lilly drugs post-legal settlement—a forced but vital move for sustainability amid FDA scrutiny. Subscribers met est at 2.58M with CEO citing record weight-loss adoption, and FY revenue guide hiked to $2.8-3B (midpoint ~2% above $2.75B est, implying ~20% growth from 2024). EBITDA cut ($275-350M) flags near-term pain, but 2Q rev guide ($680-700M vs $645M est) suggests acceleration. 15% premarket drop feels like panic; international strength (per MS) and transition endgame favor re-rating if H2 margins rebound to 70%+.
Branded GLP-1s carry 4-5x higher costs than compounds, risking subscriber churn if pricing backlash hits amid fierce competition from WW, RO, or direct pharma channels.
"HIMS is trading on a margin recovery that depends entirely on branded GLP-1 subscriber stickiness and insurance coverage, neither of which is guaranteed, while the company has signaled it expects profitability headwinds to persist into H2."
HIMS is executing a rational but painful transition: abandoning low-margin compounded GLP-1s (where margins collapsed as competition intensified) for branded drugs where they're a distribution partner, not manufacturer. The math is brutal near-term—gross margin fell 8 points y/y, Adjusted EBITDA halved—but the article and analyst consensus miss a critical point: HIMS' unit economics on branded GLP-1s are likely *better* than on compounded drugs, even at lower volumes. The real risk isn't the transition; it's whether subscriber growth (up 9.2% y/y, hitting 2.58M) can sustain when the TAM shifts from 'anyone wanting weight loss' to 'people willing to pay for Novo/Lilly drugs.' Q2 guidance for $35-55M Adjusted EBITDA (vs. $70M consensus) signals management expects margin pressure to persist longer than Street models. That's the tell.
If branded GLP-1 adoption slows due to insurance friction, prior authorization delays, or price resistance, HIMS loses both the margin recovery AND the subscriber growth story—leaving a company with $475M in operating expenses but no clear path to profitability. The 27% y/y OpEx growth suggests they haven't yet rightsized the cost structure for a lower-volume, higher-margin model.
"If the Novo partnership and branded GLP-1 rollout prove durable, HIMS could re-rate on higher-margin growth and international expansion, offsetting near-term EBITDA softness."
Q1 results show near-term strain as HIMS pivots from compounded GLP-1s toward branded obesity drugs. Revenue came in at $608.1m (vs $617.5m est), a loss of $0.40 per share, and adj EBITDA of $44.3m (-51% y/y), with gross margin at 65% (down from 73%). The plan to lift full-year revenue to $2.8-3.0b but compress EBITDA to $275-350m signals a margin haircut during the transition. Importantly, 2Q guides above consensus for revenue ($680-700m) imply demand remains, and a Novo partnership could unlock higher-margin, scalable growth via branded products and international expansion—if execution sticks. The risk is payer constraints and execution headwinds.
The pivot to branded GLP-1s may fail to deliver durable margin upside; higher revenue could come with persistent cost headwinds and payer/price pressures. If growth falters or regulatory/friction increases, the stock could reprice as the optionality fades.
"The shift to branded GLP-1s permanently erodes HIMS's competitive advantage and margin profile by transforming them into a commoditized distributor."
Claude, your assertion that unit economics on branded GLP-1s are 'likely better' ignores the reality of HIMS's current cost structure. By moving to branded, they lose the ability to capture the compounding spread, effectively becoming a low-moat pharmacy storefront. If subscriber growth slows, they are left with massive fixed marketing costs and no proprietary product to defend pricing. The market is rightfully pricing in a permanent impairment of their long-term operating margin profile, not just a transition hiccup.
"Branded GLP-1s' higher ARPU and platform cross-sell moat outweigh near-term gross margin pain."
Gemini, dismissing branded GLP-1 unit economics overlooks the 4-5x ARPU uplift (compounds ~$200/mo vs. branded $1,000+) cited across takes, which can more than offset 800bps gross compression if CAC/subscriber holds steady. HIMS's platform moat—customer data for cross-selling high-margin hair/ED—turns 'storefront' into a flywheel. Unflagged upside: validated DTC partner status with Novo could yield exclusivity, accelerating international scale.
"Higher ARPU on branded GLP-1s is offset by rising CAC during transition, making near-term margin recovery unlikely despite revenue acceleration."
Grok's 4-5x ARPU uplift math assumes CAC stays flat during transition—but Claude flagged 27% y/y OpEx growth, suggesting acquisition costs are *rising* as HIMS scales branded products. If CAC per subscriber jumped 15-20% while gross margin fell 800bps, the unit economics math breaks. Q2 EBITDA guide ($35-55M) implies management doesn't expect CAC normalization soon. That's the real haircut.
"ARPU uplift from branded GLP-1s won't be enough to offset CAC and OpEx headwinds; near-term margins stay depressed absent a clear H2 margin rebound."
ARPU uplift from branded GLP-1s may look large on paper, but it doesn't ensure profitable scale. CAC escalation, higher OpEx, and payer/discount headwinds compress the economics; 800bps gross margin drop plus a $35-55M EBITDA guide imply margin erosion persists. If Novo/Lilly deals cap price growth or if churn rises as coverage tightens, the supposed flywheel may stall—bearish near-term unless H2 margin rebound materializes.
HIMS is undergoing a challenging transition from low-margin compounded GLP-1s to higher-margin branded drugs, with near-term margin compression and uncertainty around subscriber growth and cost structure.
Potential exclusivity and international scale through validated DTC partner status with Novo.
Sustaining subscriber growth and managing increasing customer acquisition costs during the transition.